Executive Chairman, Co-Founder, Allogene Therapeutics Inc.
Belldegrun, an Israeli-born physician who still teaches urology at UCLA, founded cancer biopharmaceutical company Kite Pharma, which was acquired in 2017 for about $12 billion. He then co-founded Bellco Capital, which he also chairs. Belldegrun has used Bellco to fund and build several biotech companies, including Cougar Biotechnology, Agensys and Allogene Therapeutics. Belldegrun is also chair of New York-based venture capital firm Two River Group Holdings, as well as Israel-based UroGen Pharma, which is developing therapies for urinary tract cancers. In addition, he co-founded Vida Ventures, a life science venture capital firm with a portfolio of 29 companies and $1 billion in assets under management.
YEARS ON THE LA500: 8
